Loxo Oncology (NASDAQ: LOXO) announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Loxo Oncology (LOXO) Releases LOXO-101 Data; Oppenheimer Raises Price Target to $30 November 9, 2015 3:45 PM Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 TrialNovember 8, 2015 10:30 AM Form 8-K Loxo Oncology, Inc. For: Nov 05November 5, 2015 6:46 AM Loxo Oncology Announces Transition of Chief Medical OfficerNovember 5, 2015 6:45 AM